About Us

Actinogen Medical  (ACW) is an ASX-listed, biotechnology company developing an innovative treatment for cognitive impairment associated with neurological diseases amenable to modifications of raised cortisol levels inside brain cells. ‘Cognition’ relates to how a person understands and acts in the world around them. Cognitive functions include memory, reasoning, awareness and decision-making, and to a large extent, influence our personality.

Actinogen Medical’s lead drug candidate, Xanamem®has been specifically designed to block the production of cortisol – the stress hormone – in the brain. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s Disease, potentially linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in other diseases. 

Xanamem offers a promising new approach to treat cognitive impairment associated with these neurological diseases.

In the Company’s recent XanaHES Phase I trial, Xanamem exhibited a statistically significant improvement in cognition among healthy older volunteers treated with 20mg Xanamem daily, and recent human target engagement data for the drug in the brain suggests good activity of doses as low as 5mg daily. The Company is conducting a range of quality Phase II studies evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer’s disease, Fragile X syndrome, and other indication(s) with a strong scientific rationale.

Our Team

Board

DR. GEOFF BROOKE

NON-EXECUTIVE CHAIRMAN

DR. GEOFF BROOKE

Dr Brooke is a clinically trained physician turned venture capitalist with over 30 years' experience in the healthcare investment industry.
Read More

PETER WEBSE

COMPANY
SECRETARY

PETER WEBSE

Mr Webse has over 26 years of company secretarial experience and is the managing director of Platinum Corporate Secretariat Pty Ltd.
Read More

DR. GEORGE MORSTYN

NON-EXECUTIVE DIRECTOR

DR. GEORGE MORSTYN

Dr Morstyn has more than 25 years’ experience in the biotechnology industry including as Senior Vice President of Development and Chief Medical Officer at Amgen Inc.
Read More

MALCOLM McCOMAS

NON-EXECUTIVE DIRECTOR

MALCOLM McCOMAS

Mr. McComas brings 25 years of investment banking experience in M&A, debt and equity funding across multiple industry sectors.
Read More

DR. STEVEN GOURLAY

CHIEF EXECUTIVE OFFICER & MANAGING DIRECTOR

DR. STEVEN GOURLAY

Dr Gourlay has more than 30 years’ experience in the development of novel therapeutics and has significant drug regulatory experience interacting with the FDA and EMA.
Read More

LEADERSHIP TEAM

DR. STEVEN GOURLAY

CHIEF EXECUTIVE OFFICER & MANAGING DIRECTOR

DR. STEVEN GOURLAY

Dr Gourlay has more than 30 years of experience in the development of novel therapeutics and brings considerable skills and experience to Actinogen.
Read More

JEFF CARTER

CHIEF FINANCIAL
OFFICER

JEFF CARTER

Mr Carter has more than 30 years of expertise in professional accounting, investment banking, corporate finance and commercial / strategic planning roles.
Read More

TAMARA MILLER

VICE PRESIDENT DRUG DEVELOPMENT & STRATEGY

TAMARA MILLER

Tamara joined Actinogen in September 2017, and has over 20 years of international clinical and product development experience.
Read More

Michael Roberts

INVESTOR RELATIONS
Michael Roberts is a corporate communications specialist with more than 25 years’ experience working with prominent ASX 50 Australian companies.
Read More

DR Christian Toouli

HEAD OF BUSINESS DEVELOPMENT
Dr Toouli joined Actinogen in 2017 to manage the company’s business development program and has more than fifteen years of experience in business development and strategy, particularly in the biotechnology sector.
Read More

THERESE RUSSELL

HEAD OF PEOPLE & INFRASTRUCTURE

THERESE RUSSELL

Therese joined the team in 2016 and has over 20 years of experience in the financial services, investment banking and corporate advisory sectors.
Read More

AD Xanamem Clinical Advisory Board

Prof Craig Ritchie

(CHAIR)

Prof Craig Ritchie

Professor Ritchie is a world-leading authority on dementia and has been a senior investigator on more than 30 drug trials of both disease-modifying and symptomatic agents for the condition.
Read More

PROF COLIN MASTERS AO

PROF COLIN MASTERS AO

Professor Masters' research career in Alzheimer’s disease and other neurodegenerative diseases spans over 35 years. He is widely acknowledged as a major worldwide influencer on Alzheimer’s disease research.
Read More

PROF JEFFREY CUMMINGS

PROF JEFFREY CUMMINGS

Professor Cummings is a world-renowned Alzheimer’s researcher and leader of clinical trials.
Read More

Fragile X Syndrome Clinical Advisory Board

DR ELIZABETH BERRY-KRAVIS

Dr Elizabeth Berry-Kravis established the Fragile X Clinic and Research Program at Rush University Medical Center in Chicago in 1992, through which she provides care to over 700 patients with fragile X syndrome (FXS).
Read More

Dr Pam Ventola

Dr Pam Ventola has conducted evaluations of children and adults with developmental disabilities for two decades and has supported numerous international trials in developmental disabilities that involve developmental, cognitive, motor, and behavioural assessments.
Read More

Depression and Cognition Clinical Advisory Board

Prof John Harrison

Professor John Harrison is an expert psychologist with a special interest in cognition whose principal professional interest is in helping people understand, maintain, and enhance their cognitive skills.
Read More

Dr Dana C. Hilt

Dr Dana C. Hilt MD has more than 25 years of drug development experience, primarily of Central Nervous System (CNS) drugs.
Read More

Christina Kurre Olsen

Christina Kurre Olsen has more than 20 years of research expertise in neuroscience, neuropsychopharmacology, CNS therapeutics and monoclonal antibody immunotherapy.
Read More

Scientific Advisory Board

PROF BRIAN R WALKER

PROF BRIAN R WALKER

Professor Walker's prolific research over 20 years has concerned the role of glucocorticoids in metabolic syndrome and cardiovascular disease.
Read More

PROF SCOTT WEBSTER

PROF SCOTT WEBSTER

Professor Webster has held positions in both biotech and academia and his research has led to the discovery of a number of potent small molecule modulators of target enzymes and receptors, including UE2343/Xanamem.
Read More

PROF JONATHAN SECKL

PROF JONATHAN SECKL

Professor Jonathan Seckl is an academic endocrinologist (MBBS UCL, PhD London).
Read More